1. Home
  2. VOC vs MAIA Comparison

VOC vs MAIA Comparison

Compare VOC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VOC

VOC Energy Trust Units of Beneficial Interest

N/A

Current Price

$2.95

Market Cap

50.7M

Sector

Energy

ML Signal

N/A

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

N/A

Current Price

$1.16

Market Cap

44.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VOC
MAIA
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.7M
44.9M
IPO Year
2011
2022

Fundamental Metrics

Financial Performance
Metric
VOC
MAIA
Price
$2.95
$1.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
60.9K
911.7K
Earning Date
01-01-0001
11-07-2025
Dividend Yield
22.16%
N/A
EPS Growth
N/A
N/A
EPS
0.51
N/A
Revenue
$9,783,812.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$5.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.44
$0.87
52 Week High
$5.12
$2.74

Technical Indicators

Market Signals
Indicator
VOC
MAIA
Relative Strength Index (RSI) 51.37 46.50
Support Level $2.82 $1.07
Resistance Level $2.97 $1.75
Average True Range (ATR) 0.07 0.17
MACD 0.00 0.01
Stochastic Oscillator 43.25 12.50

Price Performance

Historical Comparison
VOC
MAIA

About VOC VOC Energy Trust Units of Beneficial Interest

VOC Energy Trust is a statutory trust. It is created to acquire and hold a term net profits interest for the benefit of the Trust unitholders. The underlying properties include VOC Brazos' net interests which are located in the states of Kansas and Texas. The trust is entitled to receive the net proceeds from the sale of production of oil and natural gas attributable to the underlying properties. The business and affairs of the Trust are managed by the Trustee, and neither VOC Brazos nor any of its affiliates has the ability to manage or influence the operations of the Trust.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: